抗栓治疗对ST段抬高心肌梗死患者的疗效及超敏C反应蛋白的影响(1)
 |
| 第1页 |
参见附件(1289KB，2页)。
[摘要] 目的 探讨抗栓治疗对ST段抬高心肌梗死(STEMI)患者的疗效及超敏C反应蛋白(hsCRP)的影响。方法 将本院2008年6月~2009年12月收治的60例STEMI患者分为治疗组和对照组，对照组采用常规抗栓治疗，治疗组在对照组的基础上加用替罗非班治疗，比较两组患者的临床疗效及hsCRP的变化。结果 治疗组的总有效率为83.3%，显著高于对照组的66.7%(P < 0.05)；且治疗组的hsCRP的改善显著优于对照组(P < 0.05)。结论 替罗非班是治疗STEMI较为有效的抗栓药物，其能显著降低患者的炎性反应，缓解症状。
[关键词] 抗栓治疗；ST段抬高心肌梗死；疗效；C反应蛋白
[中图分类号] R542.2+2 [文献标识码] A [文章编号] 1674-4721(2012)03(a)-0041-02
The influence of antithrombotic therapy on the curative effect and high sensitivity C reactive protein for patients with ST segment elevation myocardial infarction
SUN Xuanlong REN Caixia
Tianyun Hospital of Puyang City Oil Field General Hospital in Henan Province, Puyang 457001, China
[Abstract] Objective To investigate the influence of antithrombotic therapy on the curative effect and high sensitivity C reactive protein for patients with ST segment elevation myocardial infarction(STEMI). Methods Sixty cases of STEMI in our hospital from June 2008 to December 2009 were divided into the treatment group and the control group, the control group was given conventional antithrombotic therapy, the treatment group was given tirofiban on the basis of the control group, the two groups were compared by the clinical curative effect and the changes of hsCRP. Results The effective rate in the treatment group (83.3%) was significantly higher than that of control group (66.7%) (P < 0.05); and the improvement of hsCRP in the treatment group was better than the control group (P < 0.05). Conclusion Tirofiban is one of the effective antithrombotic drugs for STEMI which can significantly decreased the inflammatory response of the patients, and relieves the symptoms.
[Key words] Antithrombotic therapy; ST segment elevation myocardial infarction; Therapeutic effect; C reactive protein
ST段抬高心肌梗死(ST segment elevation myocardial infarction，STEMI)是冠状动脉完全闭塞的一组急性心血管事件，其病情较重，患者的死亡率较高。炎症反应和血小板活化在STEMI的发生和发展起着关键性的作用[1]。抗栓治疗是STEMI的基础治疗手段，其能纠正NSTEMI心肌缺血情况，有效地缓解患者的临床症状。本院在2008年6月~2009年12月采用替罗非班治疗STEMI患者30例，疗效满意，现报道如下：
1 资料与方法 ......
您现在查看是摘要介绍页，详见PDF附件(1289KB，2页)。